Atai life sciences announces first subject dosed in the phase 1 iv-to-subcutaneous bridging study of pcn-101 (r-ketamine)

New york and berlin, april 13, 2023 (globe newswire) -- atai life sciences (nasdaq: atai) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been dosed in perception neuroscience's phase 1 intravenous-to-subcutaneous bridging study of pcn-101 (r-ketamine).
ATAI Ratings Summary
ATAI Quant Ranking